Skip to main content
Article
Drotrecogin alfa (activated) treatment in severe sepsis from the global
All Scholarly Works
  • Jay Steingrub, MD, Baystate Health
Document Type
Article, Peer-reviewed
Publication Date
10-1-2005
Abstract
OBJECTIVE: To provide further evidence for the efficacy and safety of drotrecogin alfa (activated) treatment in severe sepsis. DESIGN: Single-arm, open-label, trial of drotrecogin alfa (activated) treatment in severe sepsis patients. Enrollment began in M
Publication ISSN
1478-9515
Citation Information
Crit Care Med. 2005 Oct;33(10):2266-77.